← BioTransfer GEO Dataset Finder
GEO series

Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy

GSE310619 Homo sapiens (human) RNA-seq (gene expression) 16 samples Submitted 2025/12/01 Platform GPL26167
At a glance

RNA-seq (gene expression) · human · 16 samples

What it is
RNA-seq (gene expression)Gene activity measured by sequencing. The summary does not mention single-cell work, so this is most likely bulk: one average per sample, the usual starting point for comparing groups.
Organism
Homo sapiens (human)
Topic
Ewing sarcomaThis series is part of our curated briefing on it.
Samples
16 samples: 4 × mouse xenograft, vehicle, day 5 (T1), vs 4 × mouse xenograft, Dinutuximab beta, day 5 (T1), vs 4 × mouse xenograft, vehicle, 11 (T2), vs 4 × mouse xenograft, Dinutuximab beta, 11 (T2),Groups are read from the sample names, not from the paper. Check the list below.
Data you can get
A processed table (series matrix) and supplementary files from NCBI; the raw sequencing reads from ENA. Which of these hold counts depends on the study, so check the file list.
Paper
Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapyiScience · 2026
Summary (written by the submitters)
Ewing sarcoma is a rare and aggressive cancer of the bone and soft tissues that mainly affects children and young adults. Despite intensive multimodal therapy, the prognosis of patients with metastatic or recurrent disease remains poor. Therefore, novel therapeutic approaches are needed to improve the outcomes of patients with Ewing sarcoma.
Read the full summary ↓
The disialoganglioside GD2 is highly expressed on Ewing sarcoma cells, making this tumor eligible for treatment with Dinutuximab beta, a monoclonal antibody targeting this antigen. Through in vitro and in vivo approaches, this study demonstrated that Dinutuximab beta effectively suppressed tumor growth by 60% (p=0.0135 vs vehicle) and improved survival rate by 68% (p=0.0006 vs vehicle) in a mouse model xenograft. The combination therapy with doxorubicin demonstrated superior efficacy compared to monotherapy, with enhanced tumor suppression (86%; p=0.0009 vs vehicle) and an extension of survival rate (146%; p=0.000025 vs vehicle). Overall, this study showed that Dinutuximab beta is effective against Ewing sarcoma, especially in combination with the standard induction chemotherapy regimen for this tumor. Integrating Dinutuximab beta into the standard chemotherapy regimen for Ewing sarcoma offers a promising new therapeutic approach that can potentially improve the prognosis for patients with high-risk disease, offering a more effective alternative to existing treatments.
Published in
Dinutuximab beta effectively treats Ewing sarcoma when combined with chemotherapy
Frapolli R, Meroni M, Bello E et al. · iScience 2026 · PMID 41541690 · doi:10.1016/j.isci.2025.114449
This dataset
Open GSE310619 in finder → Find more human RNA-seq datasets → Ewing sarcoma landscape →
Download · which file do I need?

Direct links to NCBI and ENA, no account and no request form. Pick by what you want to do: take the small processed table to look, the supplementary files to re-analyse, or the original raw data to start over.

1 · Just have a look

Processed table

The series matrix: one table of values per sample as the submitters processed it. The smallest download, and it opens in Excel or R. Start here to see what the data look like.

Series matrix ↓
2 · Re-analyse it

Supplementary files

The count tables and other files the authors uploaded. Take only the samples you need, or the whole study as GSE310619_RAW.tar (it can run to tens of gigabytes).

All supplementary files ↗ Whole study · RAW.tar ↓
3 · Start from the raw reads

Raw sequencing reads

The original FASTQ files, straight from the sequencer, held at ENA. Large, and you align them yourself, so only choose this if you need to re-process the study from scratch.

Raw reads on ENA ↗

What the files usually look like: For RNA-seq the counts are usually a table among the supplementary files (look for 'counts', 'expression', 'FPKM' or 'TPM' in the file name). The series matrix of a sequencing study is sometimes nearly empty.

Also filed as BioProject PRJNA1366592 and SRA study SRP647044. Searching any of these in the dataset finder brings you back here.

NCBI GEO page ↗ Paper (PMID 41541690) ↗
Study design
4 × mouse xenograft, vehicle, day 5 (T1), vs 4 × mouse xenograft, Dinutuximab beta, day 5 (T1), vs 4 × mouse xenograft, vehicle, 11 (T2), vs 4 × mouse xenograft, Dinutuximab beta, 11 (T2),

Supports a between-group comparison across 16 samples.

How we read this: 4 replicated groups read from 16 sample titles; they account for 16 of them. These groups are guessed from the sample names, not taken from the paper, so check them against the sample list below before relying on them.

Samples in this study
More Ewing sarcoma datasets

Search all human RNA-seq datasets in GEO →

Share this dataset

Metadata from NCBI GEO, cached and refreshed periodically — the NCBI page above is authoritative. Downloads link straight to NCBI/ENA; nothing is proxied through BioTransfer.